Development of a suitable salt form for a GPR40 receptor agonist

Organic Process Research and Development

Volumn 15, Issue 1, 2011, Pages 104-111

  Morrison, Henry ^a   Jona, Jonan ^a   Walker, Shawn D ^a   Woo, Jacqueline C S ^a   Li, Lan ^a   Fang, Jan ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM SALTS; CLINICAL DEVELOPMENT; CRYSTALLINITIES; DRUG SUBSTANCES; FREE ACIDS; LONG-TERM DEVELOPMENT; QUALITY ATTRIBUTES; TYPE-2 DIABETES;

AMINO ACIDS; DRIERS (MATERIALS);

SALTS;

EID: 79251476856     PISSN: 10836160     EISSN: 1520586X     Source Type: Journal    
DOI: 10.1021/op100204u     Document Type: Article

References (16)

1. Woo, J. C. S.; Cui, S.; Walker, S. D.; Faul, M. M. Tetrahedron 2010, 66, 4730-4737
2. Xie, Y.; Tao, W.; Morrison, H.; Chiu, R.; Jona, J.; Fang, J.; Couchon, N. J. Pharm. Sci. 2008, 362, 29-36
3. Briscoe, C. P.; Peat, A. J.; McKeown, S. C.; Corbett, D. F.; Goetz, A. S.; Littleton, T. R.; McCoy, D. C.; Kenakin, T. P.; Andrews, J. L.; Ammala, C.; Fornwald, J. A.; Ignar, D. M.; Jenkinson, S. Br. J. Pharmacol. 2006, 148, 619-628
4. Itoh, Y.; Hinuma, S. Hepatol.Res. 2005, 33, 171-173
5. Feng, D. D.; Luo, Z.; Roh, S. G.; Hernandez, M.; Tawadros, N.; Keating, D. J.; Chen, C. Endocrinology. 2006, 147, 674-682
6. Fujiwara, K.; Maekawa, F.; Yada, T. Am.J.Physiol.Endocrinol.Metab. 2005, 289 E670-677
7. Schnell, S.; Schaefer, M.; Schofl, C. Mol. Cell. Endocrinol. 2007, 263, 173-180
8. Song, F.; Lu, S.; Gunnet, J.; Xu, J. Z.; Wines, P.; Proost, J.; Liang, Y.; Baumann, C.; Lenhard, J.; Murray, W. V.; Demarest, K. T.; Kuo, G. H. J. Med. Chem. 2007, 50, 2807-2817
9. Gould, P. L. Int. J. Pharm. 1986, 33, 201-217
10. Bastin, R. J.; Bowker, M. J.; Slater, B. J. Org Process Res Dev. 2000, 4, 427-435
11. Stahl, P. H.; Wermuth, C. G. Handbook of Pharmaceutical Salts: Properties, Selection and Use; Helvetica Chimica Acta: Zurich, 2002.
12. Gross, T. D.; Schaab, K.; Ouellette, M.; Zook, S.; Reddy, J. P.; Shurtleff, A.; Sacaan, A. I.; Aebic-Kolbah, T.; Bozigian, H. Org.Process Res.Dev. 2007, 11, 365-377
13. Maurin, M. B.; Rowe, S. M.; Koval, C. A.; Hussain, M. A. J. Pharm. Sci. 1994, 83 (10) 1418-1420
14. Kumar, L.; Amin, A.; Bansal, A. K. Pharm.Technol. 2008, 3 (32) 128-146
15. For a GMP scale-up of an ethanolamine salt, see: Deussen, H.-J.; Jeppesen, L.; Scharer, N.; Junager, F.; Bentzen, B.; Weber, B.; Weil, V.; Mozer, S. J.; Sauerberg, P. Org. Process Res. Dev. 2004, 8, 363
16. Slightly improved crystallinity in the GMP batch was attributed to improved control of the desolvation (Form E - Form C) process that employed a humid nitrogen sweep through the filter cake to induce the conversion.